Recent Updates
Recently added Catalysts
MLTX Negative Sentiment Score: 20/100

MoonLake Immunotherapeutics Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – MLTX

Key Takeaway: MoonLake Immunotherapeutics is embroiled in a class action securities lawsuit filed by Levi & Korsinsky, LLP. The lawsuit targets investors who experienced losses between March 10, 2024, and September 29, 2025, alleging that the company made misleading statements regarding its drug candidate SLK. Specific claims include that SLK's purported advantages over BIMZELX were unfounded and lacked a reasonable basis. Affected investors are urged to act promptly to request lead plaintiff status or to participate in the class action at no cost.

Market Sentiment Analysis

CONCERNS & RISKS

  • MoonLake is facing a class action lawsuit for alleged securities fraud.
  • The lawsuit claims false statements were made regarding the effectiveness of its sole drug candidate, SLK.
  • Investors may suffer significant losses due to the ongoing legal implications.

Full Press Release Details

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team:
MLTX investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) It's sole drug candidate, SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) SLK’s distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; (3) SLK’s distinct Nanobody structure supposed increased tissue penetration would not translate to clinical efficacy; and (4) based on the foregoing, defendants lacked a reasonable basis for their positive statements regarding SLK’s purported superiority to monoclonal antibodies.
WHAT'S NEXT? If you suffered a loss in MoonLake during the relevant time frame, you have until December 15, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor

Tags

Frequently Asked Questions

What is the lawsuit against MoonLake Immunotherapeutics about?

The lawsuit alleges securities fraud affecting investors from March 2024 to September 2025.

How can I contact Levi & Korsinsky regarding the lawsuit?

You can email Joseph E. Levi at jlevi@levikorsinsky.com or call (212) 363-7500.

What are the key allegations in the complaint?

The complaint claims false statements about SLK's clinical benefits compared to BIMZELX.

Is there a cost to participate in the class action?

No, class members can seek compensation without any out-of-pocket costs.

When is the deadline to become a lead plaintiff?

The deadline to request lead plaintiff status is December 15, 2025.

Last updated: Dec 12, 2025